U.S.-based NeoStem Signs Twin Agreements To Provide Stem Cell Treatments To Chinese Hospitals
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The New York-headquartered biopharmaceutical firm NeoStem Inc has signed twin agreements to provide a leading-edge stem cell-based orthopedic therapy to two Chinese hospitals
You may also be interested in...
Head Of U.S. National Institutes Of Health Warns Court Ban On Funding For Embryonic Stem Cell Research Could Trigger Flight Of Best Scientists To Rival Centers Abroad
BEIJING - As lawyers for the United States Department of Justice and for those seeking to halt all federal funding for embryonic stem cell research prepare for a new round of battle in a U.S. Court of Appeals, the head of the National Institutes of Health is warning that a funding freeze could trigger an exodus of the best embryonic stem cell scientists to rival centers abroad
While China Pulls Ahead In Regenerative Medicine Research, Its Loosely Regulated Stem Cell Treatment Centers Raise International Concerns
BEIJING - China's ascendancy as a world power in regenerative medicine has been marked by a rapid-fire increase in the writing of top-level papers in the field for international scientific publications, but also by the appearance of controversial stem cell centers that sometimes offer treatments that have not been tested in clinical trials
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).